Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582956 · ClinicalTrials.gov registry record · NA
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT03582956: Clinical Trial NA study, sponsored by Yale University.
NCT03582956 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03582956, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes. In addition, this study will also examine the role of fatty liver disease on the insulin resistance of obesity in adolescents with type 1 diabetes.
Primary Outcome
Insulin function will be measured using a euglycemic hyperinsulinemic clamp procedure. A clamp measures insulin sensitivity. During the low does insulin phase, this reflects hepatic glucose metabolism, which is reported here. A higher glucose infusion rate number indicates more sensitivity to insulin; a lower number means more resistance to insulin.
Interventions
- PROCEDURE Euglycemic hyperinsulinemic clamp with tracer enhancement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2022-08-12 |
| Phase | NA |
Why NCT03582956 stopped before completion
NCT03582956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Euglycemic hyperinsulinemic clamp with tracer enhancement is the first listed.
NCT03582956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03582956 about?
NCT03582956 is a clinical study titled "Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes". The purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes. In addition, this study will also examine the role of fatty liver disease on t...
What is the current status of trial NCT03582956?
This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2019-01-01. Estimated completion is 2022-08-12.
What interventions are being tested in trial NCT03582956?
The interventions under investigation include: Euglycemic hyperinsulinemic clamp with tracer enhancement (PROCEDURE).
Who is sponsoring clinical trial NCT03582956?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03582956's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI